Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Key to changes
?
Text removedfrom 2022 Q2- Text added to 2022 Q3
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. senior Bad
|
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
Coll freshman Bad
|
New words:
anda, andmandatory, applicablela, ascribed, Biomedical, Biopharma, Bioscience, byhold, Deed, direct, ers, facilitating, frame, Group, haddrew, Hudson, ina, inthe, ny, Oceanview, October, partof, renamed, Restructuring, rounding, subsidiary, Subtopic, surviving, thethree, unpaid, YishengBio, YS
Valuein 2022 Q2 filing- Value in 2022 Q3 filing
Original filings
Filing view